JPRN-jRCT2071200074已完成未知
Expanded Access Protocol of Givosiran for Patients with Acute Hepatic Porphyria (AHP)
Fujii Norihisa0 个研究点目标入组 10 人开始时间: 2020年12月24日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Male or female, >=12 years of age.
- •2. Documented diagnosis of AIP, HCP, VP, or ADP.
- •3. Has adequate venous access as judged by the Investigator for study sample collections.
- •4. Patient is able to understand and is willing and able to comply with the study requirements and to provide written informed consent. In patients under the age of legal consent, the legal guardian(s) must provide informed consent and the patient should provide assent per local requirements.
- •5. Be willing to comply with the contraceptive requirements during the study period.
排除标准
- •1. Has any of the following laboratory parameter assessments at screening
- •a. ALT >2xULN
- •b. Total bilirubin (TBL) >1.5xULN. Patients with elevated TBL that is secondary to documented Gilbert's syndrome are eligible if the TBL is <2xULN
- •c. eGFR <15 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula or the Schwartz Bedside Formula Appendix 1.(Levey 2009)
- •2. Currently enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study(s), or receiving other investigational agent(s).
- •3. On an active liver transplantation waiting list.
- •4. Active infection with hepatitis B or hepatitis C previously identified by serology.
- •5. Known human immunodeficiency virus (HIV) infection.
- •6. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or to GalNAc.
- •7. History of intolerance to SC injection(s).
- •8.Any condition (eg, medical concern or alcohol or substance abuse) which, in the opinion of the Investigator, would make the patient unsuitable for dosing or which could interfere with the study compliance or the patient's safety. This includes significant active and poorly controlled (unstable) cardiovascular, neurologic, gastrointestinal, endocrine, renal, or psychiatric disorders unrelated to porphyria identified by key laboratory abnormalities or medical history.
- •9. Has a major surgery planned during the first 6 months of the study.
- •10. History of serious infection within one month prior to Screening.
- •11. Had a malignancy within 2 years prior to screening, except for basal or squamous cell carcinoma of the skin, cervical in-situ carcinoma, or breast ductal carcinoma, that has been successfully treated.
- •12. Female patient is pregnant or breastfeeding.
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic PorphyriaAcute Hepatic PorphyriaNCT04056481Alnylam Pharmaceuticals
Available
不适用
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CIDPChronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT04777734argenx
Available
不适用
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221GBMGlioblastoma MultiformeNCT02146066Northwest Biotherapeutics
招募中
3 期
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelJPRN-jRCT2033230370Gina Bonaccorso10
No Longer Available
不适用
An Open-Label, Expanded Access Protocol of Iniparib Breast CancerBreast CancerNCT01130259Sanofi